Search
Icaridin
go.drugbank.com/drugs/DB14074InvestigationalIcaridin has been commonly used as a topically-applied insect repellent in various countries but was officially licensed for use in the United States in 2001 and Canada in 2012 [L4595]. … Icaridin is reported to be less irritating than [Diethyltoluamide], another common insect repellant, and products containing up to 20% of icaridin are considered safe for long-term use in adults [A39231
Technetium Tc-99m mebrofenin
go.drugbank.com/drugs/DB09137ApprovedWithdrawnCurrently available within a sterile kit, Tc-99m Mebrofenin is indicated for imaging of the liver and gallbladder.
Roxadustat
go.drugbank.com/drugs/DB04847ApprovedInvestigationalRoxadustat is a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor used to treat anemia associated with chronic kidney disease. It works by reducing the breakdown of the hypoxia-inducible factor (HIF), which is a transc...
Biapenem
go.drugbank.com/drugs/DB13028InvestigationalBiapenem has been used in trials studying the treatment of various bacterial infections. It is a carbapenem antibiotic with a methyl group on the 1-beta position, which gives it stability against degradation by dehydropeptidase I.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseISIS 325568
go.drugbank.com/drugs/DB06099InvestigationalIt was under investigation in clinical trial NCT00519727 (Safety Study of ISIS 325568 in Healthy Volunteers) for lowering blood glucose and helping control type 2 diabetes. … ISIS 325568 is a generation 2.2 antisense drug that targets the glucagon receptor (GCGR).
YSIL6
go.drugbank.com/drugs/DB05017ExperimentalYSIL6 is a small-molecule drug in development for the treatment of inflammatory diseases, including rheumatoid arthritis and psoriasis.
SOT-107
go.drugbank.com/drugs/DB05337InvestigationalThis drug treat for a type of brain cancer called a high grade glioma brain tumour. About half of all brain tumours are gliomas.
DNB-001
go.drugbank.com/drugs/DB05757InvestigationalDNB-001 is a first-in-class oral therapy with dual mechanism of action, which is initially being developed for the treatment of glaucoma.
Etaracizumab
go.drugbank.com/drugs/DB12213InvestigationalEtaracizumab has been investigated for the treatment of Psoriasis, Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer, and Stage III Renal Cell Cancer.
ICG-136
go.drugbank.com/drugs/DB17343ExperimentalICG-136 is a compound chimeric antigen receptor (cCAR) T-cell therapy developed by iCell Gene Therapeutics. It was investigated for the treatment of acute myeloid leukemia.